<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0003128'>Lactic acidosis</z:hpo> has been associated with use of <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001943'>Hypoglycemia</z:hpo> is a major concern using <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to compare the risk of <z:hpo ids='HP_0003128'>lactic acidosis</z:hpo> and <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> among patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> using oral antidiabetes drugs </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: This study is a nested case-control analysis using the U.K.-based General Practice Research Database to identify patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who used oral antidiabetes drugs </plain></SENT>
<SENT sid="4" pm="."><plain>Within the study population, <z:hpo ids='HP_0000001'>all</z:hpo> incident cases of <z:hpo ids='HP_0003128'>lactic acidosis</z:hpo> and <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> were identified, and <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> case subjects were matched to up to four control patients based on age, sex, practice, and calendar time </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Among the study population of 50,048 type 2 diabetic subjects, six cases of <z:hpo ids='HP_0003128'>lactic acidosis</z:hpo> during current use of oral antidiabetes drugs were identified, yielding a crude incidence rate of 3.3 cases per 100,000 person-years among <z:chebi fb="0" ids="6801">metformin</z:chebi> users and 4.8 cases per 100,000 person-years among users of <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Relevant comorbidities known as risk factors for <z:hpo ids='HP_0003128'>lactic acidosis</z:hpo> could be identified in <z:hpo ids='HP_0000001'>all</z:hpo> case subjects </plain></SENT>
<SENT sid="7" pm="."><plain>A total of 2,025 case subjects with <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and 7,278 matched control subjects were identified </plain></SENT>
<SENT sid="8" pm="."><plain>Use of <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> was associated with a materially elevated risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>The adjusted odds ratio for current use of <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> was 2.79 (95% CI 2.23-3.50) compared with current <z:chebi fb="0" ids="6801">metformin</z:chebi> use </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0003128'>Lactic acidosis</z:hpo> during current use of oral antidiabetes drugs was very rare and was associated with concurrent comorbidity </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0001988'>Hypoglycemic episodes</z:hpo> were substantially more common among <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> users than among users of <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
</text></document>